» Articles » PMID: 22806097

Chronic Inflammation and Lung Fibrosis: Pleotropic Syndromes but Limited Distinct Phenotypes

Overview
Journal Mucosal Immunol
Publisher Elsevier
Date 2012 Jul 19
PMID 22806097
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Experimental models of lung fibrosis have been disappointing in predicting therapeutic responses to a wide variety of interventions in clinical fibrosing lung diseases. There are multiple potential reasons, but this fundamentally calls into question the validity of the models and their fidelity to clinical syndromes. We propose that the clinical diseases associated with pulmonary fibrosis, although manifesting a broad array of widely different clinical presentations and features, result in essentially two distinct phenotypes of fibrosis that we will describe. The most common and problematic of these are not effectively modeled experimentally. In this review, we present several clinical entities as examples of the phenotypic distinctions. The first two represent the extremes: postinflammatory fibrosis observed in hypersensitivity pneumonitis (HP) and dysregulated matrix deposition as observed in idiopathic pulmonary fibrosis (IPF). We also present a third clinical entity, that of lung disease associated with rheumatoid arthritis (rheumatoid lung), representing a condition that can manifest as either phenotype, and offering a potential opportunity to explore the mechanisms underlying the pathogenesis of the two distinct fibrotic phenotypes.

Citing Articles

Mesenchymal stem cell application in pulmonary disease treatment with emphasis on their interaction with lung-resident immune cells.

Hazrati A, Mirarefin S, Malekpour K, Rahimi A, Khosrojerdi A, Rasouli A Front Immunol. 2024; 15:1469696.

PMID: 39582867 PMC: 11581898. DOI: 10.3389/fimmu.2024.1469696.


Pseudomonas aeruginosa Infection and Inflammation in Cystic Fibrosis: A Pilot Study With Lung Explants and a Novel Histopathology Scoring System.

Malhotra S, Yang C, Nicholson K, Wozniak D, Hayes Jr D Lung. 2024; 202(5):711-722.

PMID: 39096413 DOI: 10.1007/s00408-024-00733-y.


Mechanisms of Bleomycin-induced Lung Fibrosis: A Review of Therapeutic Targets and Approaches.

Mohammed S, Al-Saedi H, Mohammed A, Amir A, Radi U, Sattar R Cell Biochem Biophys. 2024; 82(3):1845-1870.

PMID: 38955925 DOI: 10.1007/s12013-024-01384-9.


CXCR3-independent role of CXCL10 in alveolar epithelial repair.

Zhang Y, Liang J, Ye J, Liu N, Noble P, Jiang D Am J Physiol Lung Cell Mol Physiol. 2024; 327(2):L160-L172.

PMID: 38771132 PMC: 11687959. DOI: 10.1152/ajplung.00301.2023.


Biomaterial-mediated intracellular control of macrophages for cell therapy in pro-inflammatory and pro-fibrotic conditions.

Tylek T, Wong J, Vaughan A, Spiller K Biomaterials. 2024; 308:122545.

PMID: 38547831 PMC: 11264195. DOI: 10.1016/j.biomaterials.2024.122545.